As a pioneer in innovative chaperone technology, SOLA Biosciences Inc. will present its compelling preclinical proof-of-concept data for SOL-257, a targeted gene therapy for misfolded TDP-43 in Amyotrophic Lateral Sclerosis, at Neuroscience 2023 in Washington, D.C. on November 15 and the ALS One Symposium on November 17.
November 9, 2023
· 2 min read
